Biosimilar Monoclonal Antibodies : Global Product Intelligence Industry Analysis 2022


Posted November 14, 2017 by submission

Infinium Global Research has added a new report on Global Biosimilar Monoclonal Antibodies Market. The report predicts the market size of Biosimilar Monoclonal Antibodies is expected to reach XX billion by 2022.

 
Infinium Global Research has added a new report on Global Biosimilar Monoclonal Antibodies Market. The report predicts the market size of Biosimilar Monoclonal Antibodies is expected to reach XX billion by 2022.
The Biosimilar Monoclonal Antibodies Market is driven by rituximab and infliximab submarkets, the rituximab submarket is accounted as the highest holding market share submarket and the infliximab submarket will become the leading submarket by 2018 continuing its dominance until 2022. A monoclonal antibody is a type of protein made in the laboratory that can bind to substances in the body, including cancer cells. A monoclonal antibody is made so that it binds to only one substance to treat different types of cancer. There are several types of monoclonal antibodies that are being used to treat certain types of cancer. Laboratory production of monoclonal antibodies is produced from clones of only one cell which means that every monoclonal antibody produced by the cell is the same due to which they are called as biosimilar monoclonal antibodies. Each monoclonal antibody recognizes one particular protein. They work in different ways depending on the protein they are targeting, hence different monoclonal antibodies are required to be made to target different types of cancers.
Get a Sample Report @ https://www.infiniumglobalresearch.com/Reports/MakeSampleRequest/72

Segments Covered:
The report segments the global biosimilar monoclonal antibodies market by drug class and by application.The market segmentation based on drug class includes, rituximab, infliximab, abciximab, trastuzumab, adalimumab, and bevacizumab. Moreover, based on application the biosimilar monoclonal antibodies market is segmented into oncology, chronic and auto immune diseases, growth hormone deficiency and infectious diseases.
Companies Profiled:
Pfizer Inc
Novartis AG
Reliance Life Sciences
Allergan plc
Coherus BioSciences Inc
Biocon
Dr. Reddy’s Laboratories Ltd.
Boehringer Ingelheim GmbH
BioXpress Therapeutics SA
Intas Pharmaceuticals Limited
BIOCAD
Genor BioPharma Co. Ltd
Celltrion Inc

Make an Enquiry @ https://www.infiniumglobalresearch.com/Reports/MakeEnquiryRequest/72

Key topics covered:
1. Report Overview
2. Executive Summary
3.Global Biosimilar Monoclonal Antibodies Market Overview
4. Global Biosimilar Monoclonal Antibodies Market, by Drug Class, (USD Million) 2015 – 2022
5. Global Biosimilar Monoclonal Antibodies Market, by Application, (USD Million) 2015 – 2022
6. Global Biosimilar Monoclonal Antibodies Market, by Region, (USD Million) 2015 – 2022
7 Company Profiles

Click to View Complete Report @ https://www.infiniumglobalresearch.com/healthcare_medical_devices/global_biosimilar_monoclonal_antibodies_market
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By infinium global research
Country India
Categories Business
Tags global biosimilar monoclonal antibodies market , global biosimilar monoclonal antibodies market report , global biosimilar monoclonal antibodies market segments , global biosimilar monoclonal antibodies market volume , market share analysis biosimilar monoclonal antibodies market , top 10 companies biosimilar monoclonal antibodies market
Last Updated November 14, 2017